News
ASPHF
8.48
NaN%
--
Weekly Report: what happened at ASPHF last week (0908-0912)?
Weekly Report · 09/15 11:44
Weekly Report: what happened at ASPHF last week (0901-0905)?
Weekly Report · 09/08 11:46
Weekly Report: what happened at ASPHF last week (0825-0829)?
Weekly Report · 09/01 11:40
Weekly Report: what happened at ASPHF last week (0818-0822)?
Weekly Report · 08/25 11:54
Ascentage Pharma Group International GAAP EPS of -$0.24, revenue of $32.6M
Seeking Alpha · 08/21 16:33
Weekly Report: what happened at ASPHF last week (0811-0815)?
Weekly Report · 08/18 11:44
Weekly Report: what happened at ASPHF last week (0804-0808)?
Weekly Report · 08/11 11:53
Weekly Report: what happened at ASPHF last week (0728-0801)?
Weekly Report · 08/04 11:56
Weekly Report: what happened at ASPHF last week (0721-0725)?
Weekly Report · 07/28 11:57
Weekly Report: what happened at ASPHF last week (0714-0718)?
Weekly Report · 07/21 11:45
Weekly Report: what happened at ASPHF last week (0707-0711)?
Weekly Report · 07/14 11:56
Ascentage Pharma appoints Veet Misra as CFO
Seeking Alpha · 07/08 05:37
Weekly Report: what happened at ASPHF last week (0630-0704)?
Weekly Report · 07/07 11:46
Weekly Report: what happened at ASPHF last week (0623-0627)?
Weekly Report · 06/30 11:54
Weekly Report: what happened at ASPHF last week (0616-0620)?
Weekly Report · 06/23 11:44
Weekly Report: what happened at ASPHF last week (0609-0613)?
Weekly Report · 06/16 11:53
Weekly Report: what happened at ASPHF last week (0602-0606)?
Weekly Report · 06/09 11:55
Weekly Report: what happened at ASPHF last week (0526-0530)?
Weekly Report · 06/02 12:05
Weekly Report: what happened at ASPHF last week (0519-0523)?
Weekly Report · 05/26 12:04
Weekly Report: what happened at ASPHF last week (0512-0516)?
Weekly Report · 05/19 11:52
More
Webull provides a variety of real-time ASPHF stock news. You can receive the latest news about Ascentage Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ASPHF
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.